3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
3
Classical hematology
3
Thoracic
2
Plasma cell
2
Lymphoid
2
Other hematologic neoplasm
1
Myeloid
1
Genitourinary
1
CNS
1
Breast
1
Conditions
Lung Neoplasms
2
Venous Thrombosis
1
Venous Thromboembolism
1
Vascular Diseases
1
Urogenital Neoplasms
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Carboplatin
463
Cisplatin
379
Paclitaxel
313
Pemetrexed
300
Docetaxel
242
Erlotinib Hydrochloride
240
Gemcitabine
232
pembrolizumab
173
Radiotherapy
172
Bevacizumab
169
Nivolumab
130
Etoposide
106
Gefitinib
95
Vinorelbine
84
durvalumab
71
atezolizumab
68
Cetuximab
65
Topotecan
61
Drug Therapy
57
Ipilimumab
55
Irinotecan
54
osimertinib
53
Radiosurgery
52
Afatinib
51
Surveys and Questionnaires
38
130-nm albumin-bound paclitaxel
38
Albumin-Bound Paclitaxel
37
Taxes
35
Cyclophosphamide
35
Surgical Procedures, Operative
34
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Tinzaparin
×
Thoracic
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled
NCT00475098
2016-09-02
TILT
Assistance Publique - Hôpitaux de Paris
Phase 3
Completed
553 enrolled